Week In Review: CStone's Hong Kong IPO To Raise $304 Million At $1.5 Billion Valuation Next Week
Article By:
ChinaBio® Today
Read
Saturday, February 16, 2019 8:30 PM EST
China will reduce the Value Added Tax on 21 rare disease treatments to 3%, starting March 1. Plus: an IPO, financings, licensing, funding rounds.
In this article: MCHI
Week In Review: New Shanghai Hi-Tech Exchange To IPO Pre-Revenue Companies
Article By:
ChinaBio® Today
Read
Saturday, February 2, 2019 4:41 PM EST
The Shanghai Stock Exchange's new Technology Innovation Board will allow still-unprofitable hi-tech companies - including biopharmas - to IPO on the exchange, though each company that debuts must have a valuation of at least $600 million to qualify.
Week In Review: 2018 Results: China Life Science Investment Hits Record Levels
Article By:
ChinaBio® Today
Read
Saturday, January 5, 2019 4:28 PM EST
Investments in China life science set new records in all categories during 2018, reflecting the increasing development of the industry. And these numbers are spectacular even in comparison to an already strong 2017.
Biotech Bonanza: 2019 Outlook
Article By:
Tarun Chandra, CFA
Read
Tuesday, January 1, 2019 1:04 PM EST
In 2019 biotech stocks will have an uphill battle, but will still provide opportunities for attractive gains.
In this article: IBB, SPY, XBI, XLV, MRNA, TSRO Also: AGN, BMY, JNJ, MRK, NVS, PFE, AMGN, LLY, AZN, GSK, ALXN, REGN, CVS, ESRX, VRTX
Week In Review: Shanghai Industrial To Start $7.3 Billion Biomedical Fund In 2019
Article By:
ChinaBio® Today
Read
Saturday, December 29, 2018 4:08 PM EST
Shanghai Industrial Investment, a state-owned conglomerate, plans to launch a $7.3 billion equity fund for China biopharma investments. The company plans to begin raising $1.5 billion in January for the fund's first tranche.
Tricida Could Topple With Lock-Up Expiration
Article By:
Don Dion
Read
Monday, December 24, 2018 12:10 AM EST
When TCDA's IPO lock-up expires on December 25, pre-IPO shareholders and company insiders will be able to cash in on gains and sell currently-restricted shares. Risk-tolerant investors should consider shorting shares ahead of the lock-up expiration.
In this article: TCDA
Week In Review: Two China Biopharmas Raise $1.4 Billion In Hong Kong IPOs
Article By:
ChinaBio® Today
Read
Saturday, December 15, 2018 4:06 PM EST
WuXi AppTec began trading on the Hong Kong Exchange following a $967 million IPO, finishing the first day of trading at the offer price. In May, the company completed a $354 million Shanghai IPO at a price that has now quadrupled after six months.
In this article: ZLAB
Legacy Housing Corporation Is A Good Old Fashioned Business
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By:
ChinaBio® Today
Read
Saturday, December 8, 2018 4:21 PM EST
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By:
ChinaBio® Today
Read
Saturday, December 1, 2018 4:44 PM EST
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
Week In Review: CStone Pharma, A Suzhou Oncology Company, Files For Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, November 17, 2018 5:26 PM EST
Suzhou's CStone Pharma has filed for a Hong Kong IPO. Founded in 2015, CStone has quickly built a portfolio of 14 oncology candidates.